ECOG Performance Status
Assessment of performance status, autonomy, and quality of life in oncology patients.
Interpretation, Use, and Clinical Significance of the ECOG Score
The Eastern Cooperative Oncology Group (ECOG) performance scale, also known as the World Health Organization (WHO) performance status or Zubrod score, is a fundamental clinical assessment tool in medical oncology. Since its publication in 1982 by Oken et al., this score has become the global gold standard for rapidly and objectively evaluating a cancer patient's quality of life, autonomy, and ability to tolerate intensive treatments.
Objectives and Importance in Therapeutic Decision-Making
In daily clinical practice, the medical oncologist faces a major challenge: determining whether the expected benefit of chemotherapy, immunotherapy, or major surgery outweighs the risks of toxicity. The ECOG score helps to:
- Guide prescription: A patient with a good performance status will better tolerate aggressive protocols.
- Assess prognosis: Regardless of the cancer stage, the ECOG score is a major predictive factor for overall survival.
- Standardize clinical trials: Almost all clinical trials require an ECOG score of 0 or 1 (sometimes 2) as an inclusion criterion.
Decision Thresholds and Clinical Caution
The ECOG score very often dictates the boundary between curative management and an exclusively palliative approach:
- ECOG 0 to 1: Patients are generally candidates for all standard treatments, including early-phase clinical trials.
- ECOG 2: Gray area. Decisions must be personalized (e.g., dose reduction, monotherapy instead of polytherapy).
- ECOG 3 to 4: Active anticancer treatments are generally contraindicated due to a risk of toxic mortality that outweighs the benefit. Supportive care (palliative care) should be prioritized to optimize comfort.
Comparison Between the ECOG Score and the Karnofsky Performance Status (KPS)
Although the Karnofsky Performance Status (KPS) was developed much earlier (1948), the ECOG score gained popularity due to its extreme simplicity. Unlike the KPS, which ranges from 0 to 100 in 10-point increments, the ECOG consists of only 6 points (0 to 5). This simplicity significantly reduces inter-observer variability (differences in assessment between two doctors). It is very common to map the two scales: an ECOG of 0 corresponds to a KPS of 90-100%, while an ECOG of 3 roughly corresponds to a KPS of 30-40%.
Limitations and Evolution (PROs)
Despite its ubiquity, the ECOG score has an inherent limitation: it is a subjective assessment made by the practitioner. Studies often show that doctors tend to "under-evaluate" their patients' symptoms compared to the patients' actual experiences. This is why modern oncology is increasingly moving towards integrating Patient-Reported Outcomes (PROs) and using wearable devices to quantify physical activity in a purely objective manner.
Clinical Summary: ECOG Score and Management
| ECOG Score | Clinical Status (WHO) | Typical Management |
|---|---|---|
| 0 - 1 | Preserved activity | Eligible for aggressive oncological treatments. |
| 2 | Limited autonomy | Case-by-case evaluation (adapted treatments). |
| 3 - 4 | High to total dependence | Supportive and palliative care prioritized. |
References:
1. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-655.
[Am J Clin Oncol]
2. Zubrod CG, Schneiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chronic Dis. 1960.
[ScienceDirect]
-
💡 Committed to scientific accuracy, if you notice any clinical or technical discrepancy, please let us know.